Related Experiment Video
Updated: Jun 12, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
Heart failure with normal ejection fraction
Meliza Goi Roscani1, Luiz Shiguero Matsubara, Beatriz Bojikian Matsubara
1Faculdade de Medicina de Botucatu, UNESP, São Paulo, Brasil. meliza10@cardiol.br
Insights
Heart failure with normal ejection fraction (HFNEF) involves diastolic dysfunction and affects older adults with comorbidities. Treatment focuses on symptom management, as specific medications show no mortality benefit.
Area of Science:
- Cardiology
- Internal Medicine
Background:
- Heart failure with normal ejection fraction (HFNEF) is a growing clinical challenge.
- It is characterized by diastolic ventricular dysfunction despite preserved ejection fraction (EF).
- Primarily affects elderly patients with comorbidities like hypertension and obesity.
Purpose of the Study:
- To review the complex physiopathology of HFNEF.
- To discuss current treatment objectives and limitations.
- To analyze prognostic factors and the role of systolic function.
Main Methods:
- Review of existing literature on HFNEF.
- Analysis of diagnostic methods like echocardiography and hemodynamic studies.
- Examination of treatment strategies and prognostic indicators.
Main Results:
- HFNEF is linked to myocardial stiffness, altered ventricular geometry, and pericardial factors.
- Treatment aims to reduce congestion and heart rate, and manage comorbidities.
- No definitive mortality benefit observed with ACE inhibitors or beta-blockers.
Conclusions:
- Prognosis is poorer with advanced age, kidney dysfunction, diabetes, severe diastolic dysfunction, and NYHA class III/IV.
- The role of systolic function in HFNEF requires further investigation.
- Comprehensive management addressing multifactorial causes is crucial.
Abstract:
Heart failure with normal ejection fraction (HFNEF) is a complex syndrome that has been broadly studied since the last decade. It is caused by diastolic ventricular dysfunction demonstrated by complementary methods, such as hemodynamic study or echocardiogram, in the presence of a normal ejection fraction (EF). It affects primarily elderly individuals with comorbidities, such as systemic arterial hypertension, coronary failure and obesity. The physiopathological mechanisms are complex and multifactorial, involving the myocardial passive stiffness, the ventricular geometry, the pericardial restraint and the interaction between the ventricles. The main objectives of the treatment were to decrease the pulmonary venous congestion and the heart rate and control the comorbidities. There is no strong evidence that the use of specific medications, such as the angiotensin-converting enzyme inhibitors or beta-blockers can influence mortality. The poorer prognostic factors include advanced age, presence of kidney dysfunction, diabetes, functional class III and IV (NYHA) and advanced-stage diastolic dysfunction, with a restrictive pattern of ventricular filling. Another aspect that has been increasingly cited in the literature is the analysis of the role of the systolic function in HFNEF cases. All these aspects are analyzed in detail in the present review.
Related Concept Videos
Pathophysiology of Heart Failure
Heart Failure IV: Classification and Diagnostic Evaluation
Heart Failure II: Pathophysiology
Heart Failure I: Introduction
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Heart Failure III: Clinical Manifestations

